NICE Enables Access to First Treatment That Targets the Underlying Pathophysiology of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1

Contributed by: Business Wire

Logo

Tags

Pharmaceutical

Health

Other Health

CRYSVITA

More Like This

Kyowa Kirin Responds to NICE’s Publication of Appraisal Consultation Document for CRYSVITA® (Burosumab), for Treatment of Rare Disease X-Linked Hypophosphataemia (XLH) in Adults1

Kyowa Kirin Presents Real-World Evidence Demonstrating Clinically Meaningful Impact of Burosumab Treatment in Adults with X-linked Hypophosphatemia

New Analysis Demonstrates Impaired Work Productivity and Increased Unemployment Rates in Adults with X-linked Hypophosphataemia (XLH)

Kyowa Kirin International and NewBridge Pharmaceuticals Enter Into Agreement to Improve Access to Medicines for Rare Disease Patients Across Middle East and North Africa

Kyowa Kirin and Swixx BioPharma announce expansion of access to POTELIGEO® (mogamulizumab) for adults living with mycosis fungoides or Sézary syndrome in Central and Eastern Europe

Pharmanovia Signs Novel Biologic In-Licensing Agreement With Lindis Biotech to Commercialise Catumaxomab for Treatment of Rare Condition, Malignant Ascites

NHS England Rolls Out Evkeeza® ▼(evinacumab) for Eligible Adults and Adolescents Aged 12 Years and Older with Homozygous Familial Hypercholesterolaemia (HoFH)

Beacon Therapeutics Announces EURETINA 2025 Presentations on 9+-Month Phase 2 DAWN and 36-Month Phase 2 SKYLINE Trial Data for laru-zova in Patients with X-linked Retinitis Pigmentosa (XLRP)